|fdaLIADAdult=* DIURIL is indicated as adjunctive therapy in [[edema]] associated with [[congestive heart failure]], [[cirrhosis|hepatic cirrhosis]], and corticosteroid and estrogen therapy.
|fdaLIADAdult=* DIURIL is indicated as adjunctive therapy in [[edema]] associated with [[congestive heart failure]], [[cirrhosis|hepatic cirrhosis]], and corticosteroid and estrogen therapy.
* DIURIL has also been found useful in [[edema]] due to various forms of renal dysfunction such as [[nephrotic syndrome]], [[glomerulonephritis|acute glomerulonephritis]], and [[renal failure|chronic renal failure]].
* DIURIL has also been found useful in [[edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.
* DIURIL is indicated in the management of [[hypertension]] either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of [[hypertension]].
DIURIL is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
* Use in Pregnancy. Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia.
Use in Pregnancy. Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia.
* [[Edema]] during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such [[edema]] causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate.
Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS, PREGNANCY). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate.
|offLabelAdultGuideSupport======Condition1=====
==Dosage==
* Developed by:
* Therapy should be individualized according to patient response. Use the smallest dosage necessary to achieve the required response.
* Class of Recommendation:
'''Adults'''
* Strength of Evidence:
''For Edema''
* Dosing Information
* The usual adult dosage is 500 mg to 1000 mg (10 mL to 20 mL) once or twice a day. Many patients with edema respond to intermittent therapy, i.e., administration on alternate days or on three to five days each week. With an intermittent schedule, excessive response and the resulting undesirable electrolyte imbalance are less likely to occur.
:* Dosage
''For Control of Hypertension''
=====Condition2=====
* The usual adult starting dosage is 500 mg to 1000 mg (10 mL to 20 mL) a day as a single or divided dose. Dosage is increased or decreased according to blood pressure response. Rarely some patients may require up to 2000 mg (40 mL) a day in divided doses.
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
|fdaLIADPed=There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
|contraindications=* [[Anuria]]
* [[Hypersensitivity]] to this product or to other sulfonamide-derived drugs.
<!--Non–Guideline-Supported Use (Adult)-->
|warnings=* Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate [[azotemia]]. Cumulative effects of the drug may develop in patients with impaired renal function.
|offLabelAdultNoGuideSupport======Condition1=====
* Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
* Dosing Information
* Thiazides may add to or potentiate the action of other antihypertensive drugs.
:* Dosage
* Sensitivity reactions may occur in patients with or without a history of allergy or [[asthma|bronchial asthma]].
=====Condition2=====
* The possibility of exacerbation or activation of [[systemic lupus erythematosus]] has been reported.
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
* Lithium generally should not be given with diuretics
<!--Pediatric Indications and Dosage-->
|clinicalTrials=* The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity.
:*'''Body as a Whole''': [[Weakness]].
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
:*'''Cardiovascular''': [[Hypotension]] including [[orthostatic hypotension]] (may be aggravated by [[alcohol]], [[barbiturates]], narcotics or antihypertensive drugs).
* Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.
=====Condition2=====
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
* Dosing Information
:* Dosage
=====Condition2=====
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
<!--Contraindications-->
|contraindications=* Condition1
<!--Warnings-->
|warnings=* Description
====Precautions====
* Description
<!--Adverse Reactions-->
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
=====Body as a Whole=====
=====Cardiovascular=====
=====Digestive=====
=====Endocrine=====
=====Hematologic and Lymphatic=====
=====Metabolic and Nutritional=====
=====Musculoskeletal=====
=====Neurologic=====
=====Respiratory=====
=====Skin and Hypersensitivy Reactions=====
=====Special Senses=====
=====Urogenital=====
=====Miscellaneous=====
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|drugInteractions=* When given concurrently the following drugs may interact with thiazide diuretics.
:*'''Alcohol, barbiturates, or narcotics''' - potentiation of [[orthostatic hypotension]] may occur.
=====Body as a Whole=====
=====Cardiovascular=====
=====Digestive=====
=====Endocrine=====
=====Hematologic and Lymphatic=====
=====Metabolic and Nutritional=====
=====Musculoskeletal=====
:*'''Antidiabetic drugs''' (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required.
:*'''Other antihypertensive drugs''' - additive effect or potentiation.
:*'''Cholestyramine and colestipol resins''' - Both cholestyramine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract.
:*'''Pressor amines (e.g., norepinephrine)''' - possible decreased response to pressor amines but not sufficient to preclude their use.
:*'''Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine)''' - possible increased responsiveness to the muscle relaxant.
=====Respiratory=====
:*'''Lithium''' - generally should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with DIURIL.
:*'''Non-steroidal Anti-inflammatory Drugs Including Selective Cyclooxygenase-2 (COX-2) Inhibitors''' - In some patients, the administration of a non-steroidal anti-inflammatory agent including a selective COX-2 inhibitor can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when DIURIL and non-steroidal anti-inflammatory agents or selective COX-2 inhibitors are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
* In some patients with compromised renal function (e.g., elderly patients or patients who are volume-depleted, including those on diuretic therapy) who are being treated with non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors, the co-administration of angiotensin II receptor antagonists or ACE inhibitors may result in a further deterioration of renal function, including possible acute renal failure. These effects are usually reversible.
=====Skin and Hypersensitivy Reactions=====
* These interactions should be considered in patients taking NSAIDs including selective COX-2 inhibitors concomitantly with diuretics and angiotensin II antagonists or ACE inhibitors. Therefore, the combination should be administered with caution, especially in the elderly.
|useInPregnancyFDA='''Teratogenic Effects - Pregnancy Category C''': Although reproduction studies performed with chlorothiazide doses of 50 mg/kg/day in rabbits, 60 mg/kg/day in rats and 500 mg/kg/day in mice revealed no external abnormalities of the fetus or impairment of growth and survival of the fetus due to chlorothiazide, such studies did not include complete examinations for visceral and skeletal abnormalities. It is not known whether chlorothiazide can cause fetal harm when administered to a pregnant woman; however, thiazides cross the placental barrier and appear in cord blood. DIURIL should be used during pregnancy only if clearly needed.
'''Nonteratogenic Effects''': Chlorothiazide may cause fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions which have occurred in the adult.
|useInPregnancyAUS=There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
=====Special Senses=====
=====Urogenital=====
=====Miscellaneous=====
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=* Because of the potential for serious adverse reactions in nursing infants from DIURIL, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInPed=* There are no well-controlled clinical trials in pediatric patients. Information on dosing in this age group is supported by evidence from empiric use in pediatric patients and published literature regarding the treatment of hypertension in such patients.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=* Clinical studies of DIURIL did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
* This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
Line 124:
Line 246:
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
<!--Administration and Monitoring-->
|administration=* Oral
|administration=* Oral
* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
* Description
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
|overdose=* The most common signs and symptoms observed are those caused by electrolyte depletion ([[hypokalemia]], [[hypochloremia]], [[hyponatremia]]) and dehydration resulting from excessive diuresis. If digitalis has also been administered, [[hypokalemia]] may accentuate [[cardiac arrhythmias]].
* In the event of overdosage, symptomatic and supportive measures should be employed. Emesis should be induced or gastric lavage performed. Correct dehydration, electrolyte imbalance, [[hepatic coma]] and [[hypotension]] by established procedures. If required, give oxygen or artificial respiration for respiratory impairment.
<!--Overdosage-->
|overdose====Acute Overdose===
====Signs and Symptoms====
* Description
* The degree to which chlorothiazide sodium is removed by hemodialysis has not been established.
====Management====
* The oral LD50 of chlorothiazide is 8.5 g/kg, greater than 10 g/kg, and greater than 1 g/kg, in the mouse, rat and dog respectively.
* Description
===Chronic Overdose===
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
<!--Pharmacology-->
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|mechAction=*
<!--Structure-->
|structure=*
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
<!--Pharmacokinetics-->
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
|howSupplied=* DIURIL Oral Suspension, 250 mg of chlorothiazide per 5 mL, is a yellow, creamy suspension, and is supplied as follows:
:*NDC 65649-311-12 bottles of 237 mL.
|howSupplied=*
|storage=* DIURIL Oral Suspension: Keep container tightly closed. Protect from freezing, –20°C (–4°F) and store at room temperature, 15-30°C (59-86°F).
|packLabel=<!--Patient Counseling Information-->
|packLabel=[[File:Diuril image.jpg|thumb|none|600px|This image is provided by the National Library of Medicine.]]
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
[[File:Diuril ingredients and appearance.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
<!--Precautions with Alcohol-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|brandNames=* DIURIL®<ref>{{Cite web | title = chlorothiazide suspension| url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd936e35-1af8-42da-bcc0-f22489d68574 }}</ref>
<!--Brand Names-->
|brandNames=* DIURIL ®<ref>{{Cite web | title =chlorothiazide suspension|url =http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bd936e35-1af8-42da-bcc0-f22489d68574 }}</ref>
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher = | date = }}</ref>
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web | last = | first = | title = http://www.ismp.org | url = http://www.ismp.org | publisher = | date = }}</ref>
DIURIL has also been found useful in [[edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.
DIURIL is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
Use in Pregnancy. Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia.
Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS, PREGNANCY). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate.
|offLabelAdultGuideSupport======Condition1=====
There is limited information regarding Off-Label Guideline-Supported Use of Chlorothiazide (oral suspension) in adult patients.
|offLabelAdultNoGuideSupport======Condition1=====
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Chlorothiazide (oral suspension) in adult patients.
|fdaLIADPed======Condition1=====
Dosing Information
Dosage
Condition2
There is limited information regarding FDA-Labeled Use of Chlorothiazide (oral suspension) in pediatric patients.
|offLabelPedGuideSupport======Condition1=====
Developed by:
Class of Recommendation:
Strength of Evidence:
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Chlorothiazide (oral suspension) in pediatric patients.
|offLabelPedNoGuideSupport======Condition1=====
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Chlorothiazide (oral suspension) in pediatric patients.
|contraindications=* Condition1
|warnings=* Description
Precautions
Description
|clinicalTrials=There is limited information regarding Clinical Trial Experience of Chlorothiazide (oral suspension) in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
|postmarketing=There is limited information regarding Postmarketing Experience of Chlorothiazide (oral suspension) in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
|drugInteractions=* Drug
Description
|useInPregnancyFDA=* Pregnancy Category
|useInPregnancyAUS=* Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Chlorothiazide (oral suspension) in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of Chlorothiazide (oral suspension) during labor and delivery.
|useInNursing=There is no FDA guidance on the use of Chlorothiazide (oral suspension) with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of Chlorothiazide (oral suspension) with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of Chlorothiazide (oral suspension) with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of Chlorothiazide (oral suspension) with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of Chlorothiazide (oral suspension) with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of Chlorothiazide (oral suspension) in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of Chlorothiazide (oral suspension) in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of Chlorothiazide (oral suspension) in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of Chlorothiazide (oral suspension) in patients who are immunocompromised.
|administration=* Oral
Intravenous
|monitoring=There is limited information regarding Monitoring of Chlorothiazide (oral suspension) in the drug label.
Description
|IVCompat=There is limited information regarding IV Compatibility of Chlorothiazide (oral suspension) in the drug label.
|overdose====Acute Overdose===
Signs and Symptoms
Description
Management
Description
Chronic Overdose
There is limited information regarding Chronic Overdose of Chlorothiazide (oral suspension) in the drug label.
|PD=There is limited information regarding Pharmacodynamics of Chlorothiazide (oral suspension) in the drug label.
|PK=There is limited information regarding Pharmacokinetics of Chlorothiazide (oral suspension) in the drug label.
|nonClinToxic=There is limited information regarding Nonclinical Toxicology of Chlorothiazide (oral suspension) in the drug label.
|clinicalStudies=There is limited information regarding Clinical Studies of Chlorothiazide (oral suspension) in the drug label.
|howSupplied=*
|packLabel=
|fdaPatientInfo=There is limited information regarding Patient Counseling Information of Chlorothiazide (oral suspension) in the drug label.
|alcohol=* Alcohol-Chlorothiazide (oral suspension) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
01.png){kind=link}